Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.lfs.2020.117477 http://scihub22266oqcxt.onion/10.1016/j.lfs.2020.117477 32119961!7089605!32119961     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Life+Sci 2020 ; 248 (ä): 117477 Nephropedia Template TP {{tp|p=32119961|t=2020. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 |pdf=|usr=}}{{32119961}} gab.com Text Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 JO: Life Sci http://www.kidney.de/pget.php?&tw=1&pmid=32119961 #FOAvip AIMS: A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries. Human to human transmission is confirmed for COVID-19 by China a month ago. Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for >8000 cases with confirmed 774 deaths. Additionally, MERS HCoV is responsible for 858 deaths out of about 2500 reported cases. The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp). MATERIALS AND METHODS: In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp. Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin. KEY FINDINGS: The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease. SIGNIFICANCE: The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection. Twit Text FOAVip Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 ????Life Sci http://www.kidney.de/pget.php?&tw=1&pmid=32119961 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32119961 #FOAvip English Wikipedia <ref>{{Cite pmid|32119961}}</ref> Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 #MMPMID32119961 Elfiky AA Life Sci 2020[May]; 248 (ä): 117477 PMID32119961show ga AIMS: A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries. Human to human transmission is confirmed for COVID-19 by China a month ago. Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for >8000 cases with confirmed 774 deaths. Additionally, MERS HCoV is responsible for 858 deaths out of about 2500 reported cases. The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp). MATERIALS AND METHODS: In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp. Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin. KEY FINDINGS: The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease. SIGNIFICANCE: The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection. |Adenosine Monophosphate/*analogs & derivatives/chemistry/metabolism[MESH] |Alanine/*analogs & derivatives/chemistry/metabolism[MESH] |Alphacoronavirus/enzymology/genetics[MESH] |Amino Acid Sequence[MESH] |Antiviral Agents/*chemistry/metabolism[MESH] |Betacoronavirus/*enzymology/genetics[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Catalytic Domain[MESH] |Computational Biology/methods[MESH] |Coronavirus Infections/*drug therapy/virology[MESH] |Drug Repositioning/methods[MESH] |Guanosine Monophosphate/*analogs & derivatives/chemistry/metabolism[MESH] |Guanosine Triphosphate/chemistry/metabolism[MESH] |Humans[MESH] |Molecular Docking Simulation[MESH] |Pneumonia, Viral/*drug therapy/virology[MESH] |Protein Binding[MESH] |Protein Conformation, alpha-Helical[MESH] |Protein Conformation, beta-Strand[MESH] |Protein Interaction Domains and Motifs[MESH] |RNA-Dependent RNA Polymerase/*antagonists & inhibitors/chemistry/metabolism[MESH] |Ribavirin/*chemistry/metabolism[MESH] |SARS-CoV-2[MESH] |Sequence Alignment[MESH] |Sequence Homology, Amino Acid[MESH] |Sofosbuvir/*chemistry/metabolism[MESH] |Thermodynamics[MESH] |Uridine Triphosphate/chemistry/metabolism[MESH]Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 (epmc).pdf DeepDyve Pubget Overpricing